Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine + HAG Regimen vs Azacytidine in Elderly Myeloid Malignancy
NCT03873311Phase 4Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Cytokines & Interferons, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of homoharringtonine, cytarabine and granulocyte colony-stimulating factor in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Overall Response Rate at 4 months. Status: unknown.
02
Drugs
homoharringtoninecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03873311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873311.